Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns

Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the ​U.S. Food and Drug Administration raised cancer-risk ‌concerns, which left no viable regulatory path for the treatment.